XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue
9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Revenue

5. Revenue

 

We generate revenue primarily through the sales of our licensed products Ameluz®, BF-RhodoLED® lamps and Xepi®. Revenue from the sales of our BF-RhodoLED® lamp and Xepi® are relatively insignificant compared with the revenues generated through our sales of Ameluz®.

 

Related party revenue relates to an agreement with Biofrontera Bioscience GmbH (“Bioscience”) for BF-RhodoLED® leasing and installation service. Refer to Note 16, Related Party Transactions.

 

An analysis of the changes in product revenue allowances and reserves is summarized as follows:

 

(in thousands):  Returns   Co-pay assistance program   Prompt pay discounts   Government and payor rebates   Total 
Balance at December 31, 2020  $217   $52   $15   $43   $327 
Provision related to current period sales   2    211    6    119    338 
Credit or payments made during the period   (142)   (263)   (5)   (113)   (523)
Balance at September 30, 2021  $77   $-   $16   $49   $142 
                          
Balance at December 31, 2021  $43   $101   $48   $54   $246 
Provision related to current period sales   8    503    16    164    691 
Credit or payments made during the period   (5)   (400)   (23)   (149)   (577)
Balance at September 30, 2022  $46   $204   $41   $69   $360